Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467115 · ClinicalTrials.gov registry record · Phase 2
Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
A Phase 2 study, sponsored by Drexel University College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01467115 is a Phase 2 study that has completed, run by Drexel University College of Medicine. The registered enrollment target is 1 participants.
The verdict
NCT01467115, a Phase 2 study, has completed, sponsored by Drexel University College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
More than 50% of Head and Neck cancers are locally advanced at presentation. Although surgery, in combination with other modalities like radiation therapy can achieve 40-50% five year survival rates, resection in the head and neck region can leave patients with poor functional and cosmetic outcomes. Due to these concerns about quality of life after surgery, there has been a lot of interest in non surgical alternatives of treatment. Various combinations of radiation, chemotherapy and biologics has showed promising results. However, questions still remain about the ideal combination treatment regimen. Based on assimilation of data from multiple sources, our study tries to identify the role of a potentially highly effective multi-modality regimen based on induction chemotherapy (Cisplatin, Docetaxel and 5 Fluorouracil) followed by combination of a biologic agent, Cetuximab, and radiation therapy.
Interventions
- BIOLOGICAL Cetuximab
- DRUG Leucovorin
- RADIATION Radiotherapy
- DRUG Filgrastim
- DRUG Erythropoetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467115
The ClinicalTrials.gov registry entry for NCT01467115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cetuximab is the first listed.
NCT01467115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467115 about?
NCT01467115 is a clinical study titled "Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer". More than 50% of Head and Neck cancers are locally advanced at presentation. Although surgery, in combination with other modalities like radiation therapy can achieve 40-50% five year survival rates, resection in the head and neck region can leave patients with poor functional and cosmetic outcomes....
What is the current status of trial NCT01467115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2010-03. Estimated completion is 2014-10-07.
What interventions are being tested in trial NCT01467115?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Leucovorin (DRUG), Radiotherapy (RADIATION), Filgrastim (DRUG), Erythropoetin (DRUG).
Who is sponsoring clinical trial NCT01467115?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.